f-13640 and Parkinson-Disease

f-13640 has been researched along with Parkinson-Disease* in 1 studies

Other Studies

1 other study(ies) available for f-13640 and Parkinson-Disease

Article	Year
Multimodal imaging study of the 5-HT NeuroImage. Clinical, 2023, Volume: 39 The leading treatment for motor signs of Parkinson's disease is L-DOPA, but, upon extended use, it can lead to levodopa-induced dyskinesia (LID). Serotonergic neurons are involved in LID etiology and previous pre-clinical studies have shown that NLX-112, a 5-HT. We compared HPK rats with LID (i.e., sensitized to the dyskinetic effects of chronic L-DOPA) and without LID (HPK-non-LID), using [. In HPK-non-LID rats, [. This neuroimaging study sheds light for the first time on the brain activation patterns of HPK-LID rats. The 5-HT Topics: Animals; Dyskinesias; Fluorodeoxyglucose F18; Levodopa; Multimodal Imaging; Parkinson Disease; Rats; Receptor, Serotonin, 5-HT1A; Serotonin	2023

Article

Year

NeuroImage. Clinical, 2023, Volume: 39

The leading treatment for motor signs of Parkinson's disease is L-DOPA, but, upon extended use, it can lead to levodopa-induced dyskinesia (LID). Serotonergic neurons are involved in LID etiology and previous pre-clinical studies have shown that NLX-112, a 5-HT. We compared HPK rats with LID (i.e., sensitized to the dyskinetic effects of chronic L-DOPA) and without LID (HPK-non-LID), using [. In HPK-non-LID rats, [. This neuroimaging study sheds light for the first time on the brain activation patterns of HPK-LID rats. The 5-HT

Topics: Animals; Dyskinesias; Fluorodeoxyglucose F18; Levodopa; Multimodal Imaging; Parkinson Disease; Rats; Receptor, Serotonin, 5-HT1A; Serotonin

2023